Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Motilal Oswal initiates coverage on Molbio Diagnostics stock with Buy, sees 21% upside. Here's why

Motilal Oswal initiated coverage on Molbio Diagnostics with a Buy rating and ₹1,800 target, implying 21% upside. The brokerage sees strong growth potential from decentralised molecular diagnostics, led by Molbio’s Truenat platform, which has 12,500+ devices across 90+ countries and 43 assays for 30 diseases.

Motilal Oswal Financial Services has given a Buy rating to Molbio Diagnostics, projecting a 21% upside from its current price. The brokerage attributes this potential to the growing demand for decentralized molecular diagnostics, driven by the Truenat platform. This portable molecular testing system has already been deployed in over 90 countries and supports 43 assays for 30 diseases.

Motilal Oswal highlights that around 75% of Molbio's revenue stems from test kits, creating a consumables-led business model similar to a razor-blade model. This model benefits from the Truenat machine, which can test for multiple diseases depending on the consumables used. The brokerage expects the company's revenue to grow at a 23% CAGR over the next three years, with operational leverage contributing to a 50% CAGR in PAT.

Beyond Truenat, Molbio has ventured into digital imaging through Prognosys, with X-ray systems used for screening patients. The brokerage anticipates Prognosys revenue to expand at a 36% CAGR over the same period. Molbio's digital pathology initiative, OptraSCAN, is still in its early stages, but is expected to become profitable in FY27.

While the brokerage remains optimistic about Molbio's growth prospects, it notes that government orders and working capital management remain key risks. The brokerage values Molbio at a 45x forward earnings multiple, with a target price of Rs 1,800, a bullish scenario of Rs 2,575, and a pessimistic outlook of Rs 1,100. Despite the challenges, Molbio's presence in 90+ countries and its 12,500+ Truenat devices deployed, coupled with the expanding global POCT infectious-disease market, provide ample room for sustained growth.

Written by urgent.news from The Economic Times - Top News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at economictimes.indiatimes.com →

More in Finance & Markets

Niobrara Capital closes inaugural fund with more than $1.5bn in commitments

New York-based private equity firm Niobrara Capital Partners has closed its debut private equity fund and related investment vehicles with more than $1.5bn in total committed capital, exceeding its…

  • Niobrara Capital closed inaugural fund Niobrara Founders Fund with >$1.5bn commitments.
  • Fund secured $1.1bn at final close, co-investment vehicles added >$0.4bn.
  • Firm specializes in middle-market B2B tech and services companies.

More from Tuesday 6 October →